We examined trends in prescription recommendations for treatment of bipolar disorder (BD) in Canada during 2002-2010.
Abbreviations

Clinical Implications
• There has been a substantial increase in the use of quetiapine during the 2002-2010 period in treatment of BD despite concerns regarding its side effects.
• The rapid rise in prescriptions for treatment of BD during the 2002-2009 period may be in part attributable to the broadening of the definition of BD to the bipolar spectrum.
• The significant drop in prescriptions during the 2009-2010 period may indicate that the rapid increase in recommendations for BD in the early 21st century has peaked.
Limitations
• We have no information on polypharmacy.
• No information is available on repeat, compared with initial, recommendations or dosages.
• No information is available on which prescriptions were filled or regarding medication adherence.
A controversial matter in the BD field is calls, for example in 2002, to expand this category into a bipolar spectrum [1] [2] [3] such that its prevalence would reach 4% to 5% of the general population. We asked whether this has impacted prescribing practices by undertaking a 9-year analysis (2002-2010) of physicians' prescriptions for BD in Canada.
Historically, lithium was the most common mood stabilizing medication for acute episodes of BD, supplemented with typical antipsychotics. The latter include chlorpromazine and haloperidol, whose use has largely been superseded. [4] [5] [6] ADs are widely used; however, induction of mania or hypomania and rapid cycling is a concern. 7, 8 Two additional drug classes are in common use, anticonvulsants 9 and atypical antipsychotics. 10 Five of the latter were approved for BD during the 2002-2010 period, although concerns exist regarding risks of weight gain, type II diabetes, and dyslipidemia. 10, 11 Overall, most prescriptions were for maintenance not acute treatments.
The CANMAT first published guidelines for management of BD in 1997, 12 and issued a recent collaborative update with the ISBD. 13 Generally, the CANMAT and ISBD guidelines agree with US guidelines 14 and those of the British Association for Psychopharmacology. 15 Despite these guidelines, there are little pharmacoepidemiologic data on consistency of clinical practice patterns with these recommendations, a significant knowledge gap addressed by our study.
Methods
The Canadian Disease and Therapeutic Index sample includes over 652 Canadian physicians stratified by physician specialty assembled from reports by physicians who record all prescriptions recommended on 2 consecutive workdays per quarter. Physicians report both their treatment prescriptions and the reasons for these recommendations. Eighty-five per cent to 91% of physicians were respondents from the previous quarter, and the proportion of GPs was relatively constant at 39% to 41% of the sample population. GPs and specialists groups were weighted separately each year to represent the total population of physicians.
We obtained IMS Brogan reports for prescriptions for BD. The data were coded according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, using the International Classification of Diseases, 9 codes: 296.00 (single manic episode), 296.40 (current or most recent episode is manic or hypomanic), 296.50 (current or most recent episode depressed), 269.60 (mixed episode), 296.70 (current or most recent episode is unspecified); also included was 296.8x (for example, 296.80, BD not otherwise specified and 296.89, BD-II). This approach ensures that all prescriptions were being recommended only for BD.
We compared prescription recommendations by GPs to specialists. The IMS Brogan specialist category combines both psychiatrists and neurologists, but the vast majority of prescriptions in this study were by psychiatrists.
The inclusion criterion for medications is all drugs prescribed for BD. The 2002 to 2010 time period was chosen as it follows calls in 2002 to expand the bipolar diagnostic category, and also it encompasses the dates on which the newest treatment for BD, the atypical antipsychotics, were approved in Canada. The Health Canada Notice of Compliance dates for these drugs were 2003, 2004, 2005, 2008 , and 2009 for olanzapine, quetiapine, risperidone, ziprasidone, and aripiprazole, respectively (the few prescriptions for the latter 2 are not reported).
Five other classes of medication were included: anticonvulsants; an IMS category designated as SRI (the selective serotonin uptake inhibitors, serotonin norepinephrine uptake inhibitors, and trazodone are included in the SRI class in this database); lithium; anxiolytics; other ADs (bupropion, mirtazapine, and moclobemide) is an IMS Brogan category that we combined with the IMS Brogan category tricyclic and related ADs. We do not report the few The data were extracted by IMS Brogan as weighted estimates for each drug at each time point separately for specialists and GPs. Those estimates not already summed by IMS Brogan were done in Excel, and Excel was used to tabulate and graph estimates by year. We tested for significant trends in drug recommendations over time with the Stata (StataCorp, College Station, TX) command nptrend, an extension of the nonparametric Wilcoxon ranksum test.
Results
We estimated the total number of prescriptions for BD, with most being by specialists (Figure 1 This far exceeds the 7.5% increase of the Canadian population during the same period. 16 However, during the 2009-2010 period the number of recommendations dropped by 24.8 %. We speculate that the following 3 factors may have contributed to the trend observed during the 2002-2009 period: the proposals to lower the threshold for diagnosis of BD [1] [2] [3] ; pharmaceutical promotion that has, for example, been shown to influence AD use 17 ; and, the increasing availability of diagnosis and treatment guidelines. This increase of drug recommendations is in accord with the large increase of rates of bipolar diagnoses, especially in children and adolescents, in the United States from 1996 to 2004. 18 The sharp decrease in recommendations during the 2009-2010 period suggests a lessening of the impact of one or more of the above factors, a trend that needs to be reassessed by future studies. Our results extend previous studies. A study 19 of treatment for mania in European hospitals between 1994 and 2004 showed a significant increase in the use of both atypical antipsychotics and anticonvulsants. In the United States, atypical antipsychotics and anticonvulsants also dominate the current drug treatments for mania. 20 The 438% increase in prescriptions for quetiapine during the 2002-2010 period is likely partly attributable to the broadening spectrum of indications for which quetiapine is recommended as a first line option. In the 2005 CANMAT guidelines, 21 quetiapine was initially recommended for first line treatment of BD, but only for acute mania. In the 2007 CANMAT guidelines, 22 quetiapine was also recommended as first line treatment for bipolar depression. Recommendation of quetiapine in first line maintenance therapy occurred in the 2009 CANMAT and ISBD guidelines. 13 Increasing polypharmacy in treatment of BD may also be a contributory factor. 23 Taken together, these issues may have been reflected in physicians' growing confidence in prescribing quetiapine with greater frequency.
The uptake of quetiapine, largely based on relatively short clinical trials on selected subjects, raises the issue as to long-term risks and benefits in real-world therapeutics. Additionally the risks to patients with comorbidities, who may have been excluded from clinical trials, need to be evaluated. In this context, the ISBD recently issued consensus guidelines for safety monitoring of BD treatments. 11 One caveat is that it is possible that the physician panel represents higher prescribers, although this seems unlikely as participation would increase their workload. Our study has other limitations, including lack of information on dosages, polypharmacy, and repeat, compared with initial, recommendations. This does not detract from our conclusions as our objective was to evaluate trends in prescription recommendations.
